Heather Ledbetter Prichard - May 24, 2023 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
Chief Operating Officer
Signature
/s/ Heather Ledbetter Prichard by Dale A. Sander as Attorney-in-Fact
Stock symbol
HUMA
Transactions as of
May 24, 2023
Transactions value $
-$157
Form type
4
Date filed
5/26/2023, 05:05 PM
Previous filing
Dec 13, 2022
Next filing
Dec 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HUMA Common Stock Options Exercise $16.4K +13.8K +150.06% $1.19 23K May 24, 2023 Direct
transaction HUMA Common Stock Sale -$57.1K -13.8K -60.01% $4.14 9.19K May 24, 2023 Direct F1
transaction HUMA Common Stock Options Exercise $77.3K +65K +707.26% $1.19 74.2K May 25, 2023 Direct
transaction HUMA Common Stock Sale -$36.8K -9.61K -12.96% $3.83 64.6K May 25, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Options Exercise $0 -13.8K -17.5% $0.00 65K May 24, 2023 Common Stock 13.8K $1.19 Direct
transaction HUMA Stock Options (right to buy) Options Exercise $0 -65K -100% $0.00* 0 May 25, 2023 Common Stock 65K $1.19 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.14 to $4.16. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.82 to $3.89. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.